Fosun Pharma USA announced the appointment of Mr. Wenjie Zhang as its new Chief Executive Officer, effective May 9, 2025. Mr. Zhang is a visionary leader with over three decades of business experience in the biopharmaceutical industry.
Fakeeh Care Group and Fosun Pharma Forge Strategic Partnership to Advance Cell & Gene Therapy and Tele-Diagnostics in Saudi Arabia
April 28, 2025, Jeddah –
Fakeeh Care Group has announced a strategic partnership with Fosun Pharma, a leading innovation-driven global healthcare company operating in the fields of pharmaceuticals, medical devices & diagnostics, and healthcare services. This partnership is part of Fakeeh Care Group’s ambitious vision to accelerate healthcare innovation in Saudi Arabia and align with the Saudi Vision 2030.
Dr. Mazen Soliman Fakeeh, President of Fakeeh Care Group, emphasized that this collaboration marks a significant step toward enhancing the Kingdom’s healthcare system by introducing cutting-edge therapeutic and diagnostic technologies. “Our goal is to build a sustainable healthcare ecosystem founded on research and innovation, and to ensure access to the world’s most advanced medical solutions,” he stated.
The partnership reflects Fakeeh Care Group’s commitment to working with trusted global players with a proven track record in pioneering and localizing advanced treatments. Fosun Pharma is an international frontrunner in biopharmaceuticals, CAR-T therapies and gene therapy. Its self-developed and approved biologics have benefited more than 750,000 patients worldwide.
In addition, Fosun Pharma has developed advanced platforms in diagnostics, medical devices, and AI-powered digital pathology, accelerating diagnostic processes and enabling effective tele-diagnostic solutions.
Commenting on the strategic alliance,Dr. Sohail Bajammal, CEO of Dr. Soliman Fakeeh Hospital in Jeddah, said: “At Fakeeh Care, we are committed to transferring and localizing advanced medical technologies in Saudi Arabia—including CAR-T treatments for hematological cancers and autoimmune disorders, gene therapies for chronic diseases, and smart tele-diagnostic and monitoring systems.”
Mr. Guo Guangchang, Chairman of Fosun International,expressed his enthusiasm for the partnership: “We look forward to establishing long-term and stable strategic cooperation with Fakeeh Care Group to realize our shared vision of delivering integrated healthcare globally. With Fosun’s global operational capabilities, we intend to achieve sustainable value growth with our Middle Eastern partners and create a new win-win ecosystem.”
The memorandum of understanding outlines that “this future collaboration is more than a technological alliance; it is a shared commitment to reshaping the healthcare landscape in the Kingdom and the region.”
This partnership aspires to become a m odel of excellence in the GCC region for integrating advanced therapeutics and tele-diagnostics, positioning Saudi Arabia as a regional hub for healthcare innovation. Through this alliance, Fakeeh Care Group and Fosun Pharma reaffirm their joint commitment to transforming patient lives through innovation, building long-term strategic partnerships, and supporting the Kingdom’s ambition to become a global center for advanced healthcare aligned with Vision 2030.
We’re excited to join the 43rd Annual J.P. Morgan Healthcare Conference from January 13-16, 2025, at the San Francisco Marriott Marquis. Let’s Meet! Our team will be at the San Francisco Marriott Marquis, located at 780 Mission St. We look forward to exploring new opportunities and collaborations as we work together to change the future of cancer care.
As we wrap-up #WCLC24 we thank everyone that visited our booth and shared the excitement around our new data release on foritinib (SAF-189s) Vs Crizotinib in First-Line ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC).
About The REMARK study:
The REMARK study is an Ongoing, Randomized, Open-label, Phase 3 trial that met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in PFS in ALK-TKI naïve NSCLC patients in interim analysis. Median PFS NR vs 13.93 months; HR=0.23, 95%CI：0.14 –0.38, p <0.0001.
Foritinib showed significant improvement of central nervous system (CNS) efficacy vs crizotinib.
CNS-TTP NR vs 19.32 months; HR=0.04, 95%CI：0.01-0.14，p<0.0001.
Foritinib showed improvement in overall survival vs crizotinib. Median OS NR vs 24.94 months; HR=0.60, 95%CI：0.30-1.20.
The safety profile of foritinib was as expected with no new findings.
Stay tuned for new data release at #ESMO24
#WCLC24 #lungcancer #ALK+ #SCLC #GoHenlius #FOSUNPHARMAUSA
Please contact Nadra Belamri nadra.belamri@fosunpharmausa.com for more info about Fosun Pharma USA
PRINCETON, N.J. [December 11, 2023, 1:00 PM ET] – Fosun Pharma USA Inc. (“Fosun Pharma USA”), a U.S.-focused specialty pharmaceutical company, with a current portfolio comprised of specialty pharmaceutical injectable products and ophthalmics, and building a portfolio of high value, branded innovative products, is pleased to announce that Chief Executive Officer, Rong Yang, and several Fosun Pharma USA executives, will be attending the 42nd Annual J.P. Morgan Healthcare Conference (JPM ’24), taking place in San Francisco, California, Jan. 8 – 11, 2024.
CEO Rong Yang will also be a panelist during Panel #1, “Navigating 2024 Capital Access, Strategic Partnerships and Cross-Border Collaboration Opportunities” at Jones Day – MSQ Global Biopharma Symposium & Networking Reception pre-JPM ‘24, co-hosted by Jones Day & MSQ Ventures, on Jan. 7, 2024, at 555 California Street, San Francisco, California.
Fosun Pharma USA will meet with potential partners and investors to address ongoing and future strategic developments within the company at JPM ’24. If you wish to book a meeting with Fosun Pharma USA’s management team, please contact us by email at scottfroom@fosunpharmausa.com.
About Fosun Pharma USA
Established in 2017 and headquartered in Princeton, New Jersey, Fosun Pharma USA Inc. is a wholly-owned subsidiary of Fosun Pharma (Group) Co., Ltd. Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun HQ”). Fosun HQ, founded in 1994 and headquartered in Shanghai, is a top global, innovation-driven pharmaceutical and healthcare industry group.
Created as an entrepreneurial business entity, Fosun Pharma USA is a U.S.-focused specialty pharmaceutical company, innovating through strategic partnerships and building its commercial presence in the United States. Fosun Pharma USA leverages its global parent company, Fosun Pharma Group, as well as a unique R&D model, to advance innovative products to patients in need.
Fosun Pharma USA is led by a team of highly experienced executives, who have a strong track record as leaders at both U.S. and European-based pharma companies, in both commercial operations and R&D. Its current portfolio is comprised of specialty pharmaceutical injectable products and ophthalmics, to build a portfolio of high value, branded innovative products.
The company is continuing to build its pipeline with late development stage (phase 2 and beyond) or commercial stage innovative products for the U.S. market, primarily. While Fosun Pharma USA can facilitate a partnership with Fosun HQ for the Chinese market, the focus is on U.S. rights for innovative biopharmaceutical products. Website: www.fosunpharmausa.com; Follow us on LinkedIn for more company updates: Fosun Pharma USA Inc.
Fosun Pharma USA Forward-Looking Statement
This presentation may include predictions, estimates, current target dates, current target indications, current plans, or other information (hereinafter “prospective information”) that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions as to said prospective information only as of the date of this presentation. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward-looking statements in light of new information, developments, changed circumstances, or future events. During today’s discussion, we will attempt to present some important factors relating to our business that may affect our aforementioned prospective information.
Fosun Pharma USA Contacts:
Media or Investors:
inquiry@fosunpharmausa.com
#
PRINCETON, N.J. [November 28, 2023, 2:00 PM ET] – Fosun Pharma USA Inc. (“Fosun Pharma USA”) announced today its abstract on ASTRIDE (NCT05468489), a phase 3 randomized, open-label study of serplulimab vs atezolizumab both in combination with chemotherapy (Carboplatin-Etoposide) in patients with extensive-stage small-cell lung cancer (ES-SCLC), has been accepted for presentation at the International Association for the Study of Lung Cancer’s (IASLC) 2023 North America Conference on Lung Cancer (NACLC), being held in Chicago, Illinois, Dec. 1 – 3, 2023.
All abstracts accepted for presentation have been published on the NACLC website.
“Our PIs are excited to present their poster on the design of the ASTRIDE Trial in Progress (TiP), which is an important milestone for the lead investigators and authors,” said Stan Lechpammer, Vice President, Medical Affairs, Innovative Medicines, Fosun Pharma USA. “This presentation provides greater insight into the ASTRIDE trial that investigates serplulimab as a potentially new therapeutic option for extensive-stage (ES) small-cell lung cancer patients (SCLC). SCLC is an aggressive malignancy, with the majority of patients presenting with extensive-stage disease at initial diagnosis. There is a high unmet need for this patient population. Beyond the potential of our TiP study design, we have committed to recruiting patients from many medically underserved communities, to address health disparities and improve health equity for ES-SCLC patients in the U.S.”
Abstract accepted for presentation’s details and key points about the study design:
| Medicine | Abstract Title | Presentation Details |
| Serplulimab | Serplulimab vs atezolizumab added to chemotherapy in patients with treatment-naive ES-SCLC in the United States – ASTRIDE Trial in Progress | Abstract #: PP01.35 Poster available: December 2 at 5:40 PM CST/6:40 PM EST |
Key Highlights about Study Design
About Serplulimab
Serplulimab is a novel anti–PD-1 (programmed cell death-1) monoclonal antibody (mAb), with a unique mode of recognition of the PD-1 receptor compared with currently available anti–PD-1 mAbs (Issafras et al. Plos One. 2021).
About the ASTRIDE Phase 3 Trial
ASTRIDE is a randomized, open-label study of serplulimab plus chemotherapy (carboplatin-etoposide) compared with atezolizumab plus chemotherapy in previously untreated patients with extensive-stage small cell lung cancer (ES-SCLC) in the United States. The primary objective for ASTRIDE is to confirm the applicability of the results of ASTRUM-005 (a global, randomized, phase 3 trial) to patients in the United States, with the current standard-of-care as the control arm, based on comments from the U.S. Food and Drug Administration (Serplulimab study protocol 2.0 final. Shanghai Henlius Biotech, Inc.; July 18, 2022).
About Small-cell Lung Cancer
Approximately 30,000-35,000 people are diagnosed with small-cell lung cancer (SCLC) each year in the United States. It is the most aggressive form of lung cancer with approximately 70% of patients presenting with extensive-stage disease (ES-SCLC), with a median overall survival of approximately 12.5 months with standard-of-care treatment.
About Fosun Pharma USA
Established in 2017 and headquartered in Princeton, New Jersey, Fosun Pharma USA Inc. is a wholly owned subsidiary of Fosun Pharma (Group) co., Ltd. Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun HQ”). Fosun HQ, founded in 1994 and headquartered in Shanghai, is a top global, innovation-driven, pharmaceutical and healthcare industry group.
Created as an entrepreneurial business entity, Fosun Pharma USA is a U.S.-focused specialty pharmaceutical company, innovating through strategic partnerships and building its commercial presence in the United States. Fosun Pharma USA leverages its global parent company, Fosun Pharma Group, as well as a unique R&D model, to advance innovative products to patients in need.
Fosun Pharma USA is led by a team of highly experienced executives, who have a strong track record as leaders at both U.S. and European-based pharma companies, in both commercial operations and R&D. Its current portfolio is comprised of specialty pharmaceutical injectable products and ophthalmics, to build a portfolio of high value, branded innovative products.
The company is continuing to build its pipeline with late development stage (phase 2 and beyond) or commercial stage innovative products for the U.S. market, primarily. While Fosun Pharma USA can facilitate a partnership with Fosun HQ for the Chinese market, the focus is on U.S. rights for innovative biopharmaceutical products. Website: www.fosunpharmausa.com; Follow us on LinkedIn for more company updates: Fosun Pharma USA Inc.
Fosun Pharma USA Forward-Looking Statement
This presentation may include predictions, estimates, current target dates, current target indications, current plans, or other information (hereinafter “prospective information”) that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions as to said prospective information only as of the date of this presentation. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward-looking statements in light of new information, developments, changed circumstances, or future events. During today’s discussion, we will attempt to present some important factors relating to our business that may affect our aforementioned prospective information.
Fosun Pharma USA Contact:
Media or Investors:
inquiry@fosunpharmausa.com
# # #
NEW YORK, NY & LONDON [Nov. 20, 2023, 6:30 AM ET] – Fosun Pharma USA and Treehill Partners (Treehill) announce the formation of a jointly operating vehicle for investment in clinical-stage assets, further solidifying the relationship between the two companies
The newly established business will be looking for high-quality, mid to late-stage assets clinically focused on the United States market. There will also be a high degree of focus on high-quality non-U.S. clinical-stage biopharma assets seeking to access the U.S. market.
The investment team’s strategy will focus on opportunities where a combination of capital, senior leadership involvement, and product development acumen will present the key to unlocking value in a short or mid timeframe.
“Over the recent quarters we have observed a tendency of stand-still in the industry resulting from limited capital being available for biotech product development. This has left a large number of programs unable to advance and ultimately reach patients, not only because clinical activities could not take place due to insufficient funding, but also because companies were not able to attract the expertise necessary to move forward successfully,” Rong Yang, CEO, Fosun Pharma USA, said. “We are combining forces with Treehill Partners given their proven track record with end-to-end capabilities bridging across corporate and product development.”
The business, jointly led by Rong Yang and Ali Pashazadeh (CEO and co-founder, Treehill Partners), will be seeking to make its first investments during 2024. The full spectrum of activities along the investment life cycle — from strategy creation, target identification and investment, over product and business development, to value realization and strategic exit options, will be jointly managed.
“This strategic step is the start of a new chapter in the growth journey of Fosun Pharma USA. Recently, we have built a detailed understanding of the landscape of opportunities and pathways for value creation in this market, which we are looking to pursue actively in an innovative structure,” Yang added. “We look forward to working with the CEOs and leadership teams of our future portfolio companies on a mission to commercialize innovative products that address significant needs of patients worldwide.”
“We have selected Fosun as a preeminent global partner who shares our work ethos and vision for novel pathways of biopharma product development, with whom we have established a trustful relationship over many years,” Pashazadeh said.
As the companies and assets in the investment portfolio mature, the partners will be looking to source third-party capital in several possible structures that will be decided on a case-by-case basis.
About Fosun Pharma USA
Established in 2017 and headquartered in Princeton, New Jersey, Fosun Pharma USA Inc. is a wholly owned subsidiary of Fosun Pharma (Group) co., Ltd. Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun HQ”). Fosun HQ, founded in 1994 and headquartered in Shanghai, is a top global, innovation-driven, pharmaceutical and healthcare industry group.
Created as an entrepreneurial business entity, Fosun Pharma USA is a U.S.-focused specialty pharmaceutical company, innovating through strategic partnerships and building its commercial presence in the United States. Fosun Pharma USA leverages its global parent company, Fosun Pharma Group, as well as a unique R&D model, to advance innovative products to patients in need.
Fosun Pharma USA is led by a team of highly experienced executives, who have a strong track record as leaders at both U.S. and European-based pharma companies, in both commercial operations and R&D. Its current portfolio is comprised of specialty pharmaceutical injectable products and ophthalmics, to build a portfolio of high value, branded innovative products.
The company is continuing to build its pipeline with late development stage (phase 2 and beyond) or commercial stage innovative products for the U.S. market, primarily. While Fosun Pharma USA can facilitate a partnership with Fosun HQ for the Chinese market, the focus is on U.S. rights for innovative biopharmaceutical products. Website: www.fosunpharmausa.com; Follow us on LinkedIn for more company updates: Fosun Pharma USA Inc.
Fosun Pharma USA Contacts:
Media or Investors:
inquiry@fosunpharmausa.com
About Treehill Partners
Treehill Partners is an international strategic and financial advisory firm exclusively focused on the healthcare sector. Its multidisciplinary team offers actionable strategic and transaction advice to healthcare CEOs, leadership teams, stakeholders, and investors, with a focus on value-creating transactions and successful corporate evolution strategies. To learn more about Treehill Partners, visit www.TreehillPartners.com.
For more information please contact:
office@treehillpartners.com
PRINCETON, N.J., Jan. 7, 2023 /PRNewswire/ — Fosun Pharma (600196.SH, 02196.HK) has recently entered into an exclusive license agreement with Shanghai Henlius Biotech, Inc. (2696.HK) for the commercialisation of Henlius independently developed anti-PD-1 monoclonal antibody (mAb) serplulimab in the United States (US). This marks an important milestone for Fosun Pharma’s development in the US.
Fosun Pharma will have the right to commercialise serplulimab upon approval in the US, and Henlius will retain responsibility for development, manufacturing, and supply. For many years, the two companies have worked closely on product commercialisation and other areas, developing consensus in terms of corporate vision and values, global development strategy, product operations, and management communication while focusing on patients’ and clinical needs. Through this collaboration, the two parties aim to intensively develop serplulimab, integrate superior resources, cooperate in securing approval, and promote its rapid launch in the United States to benefit more patients.
Mr. Wu Yifang, Chairman of Fosun Pharma, said, “We are very happy to make full use of Fosun Pharma’s accumulated innovation capabilities, internationalization advantages and commercialization capabilities over the years to promote the commercialization of an approved anti-PD-1 mAb serplulimab in the US market and help benefit more patients around the world. Fosun Pharma has always been patient-centered and clinical needs-oriented. We have been practicing internationalization strategies in the dimensions of innovative R&D, license introduction, production operation and commercialization, and continuously strengthening the construction of full capacity in global operations.”
Mr. Wenjie Zhang, Chairman and CEO of Henlius, said, “We are excited to partner with Fosun Pharma in the United States on serplulimab. The impressive clinical data of serplulimab was published in the top international medical journal and has gained international attention. As we move forward, we’ll seek approvals for additional indications in China, the US, and the European Union. In the US, Fosun Pharma has a fast-growing commercialisation team and a dedicated sales network. Together, we will, upon approval, accelerate the launch of this differentiated anti-PD-1 mAb in the US market and benefit more overseas patients with high-quality biological drugs.”
Joining Forces for a Global Blueprint
Founded in 1994, Fosun Pharma is a global innovation-driven pharmaceutical and healthcare industry group. Fosun Pharma strengthens its independent R&D and external cooperation and enriches its product pipelines, as well as promotes global networks. Thanks to its industry-leading two-way licensing capabilities and international advantages, Fosun Pharma helps maximize the value of innovative products of partners. In the international layout, Fosun Pharma focuses on building the U.S. operation center and conducts all-around capacity building in R&D, production, and sales in the local market. On the important partnership in the U.S. for serplulimab, and the potential impact on patients with lung cancer, Mr. Rong Yang, Senior Vice President of Fosun Pharma and CEO of Fosun Pharma USA Inc. said, “It is a very important step for us, an opportunity to be a part of the community, and serving patients with critical unmet needs, and making a difference every day.”
Fully leveraging the experience of biologics development and harnessing the power of innovation, Henlius has built a vertically integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle, including R&D, manufacturing and commercialisation, laying the solid foundation for a diversified and robust innovation pipeline. To date, 5 products have been successfully marketed in China, and 1 approved for marketing in overseas markets. The pipeline of products under development covers targets with great market potential, such as PD-1, HER2, EGFR, BRAF, etc. Synergising the innovation centres in China and the US and global product development teams, Henlius continues the momentum for a diversified innovation product pipeline and has conducted more than 20 clinical trials in China, the EU, the US, Australia, etc. with more than 70 clinical trial approvals worldwide. In terms of manufacturing capabilities, Henlius strictly follows the International Good Manufacturing Practice (GMP) standards for production and quality control. The products in the pipeline are produced by Henlius’s self-built manufacturing facilities, with rich production experience from clinical stages to commercialised products. Also, the manufacturing facilities have successfully passed the on-site inspection conducted by NMPA, the European Medicines Agency, the EU qualified person, and multiple international business partners, and are certified by China and EU GMP. Henlius’ strong R&D capabilities, international-standard quality management system, and production capacity enable Henlius to boost the global commercialisation of its products.
About HANSIZHUANG
HANSIZHUANG, as the product is known in China, (recombinant humanised anti-PD-1 monoclonal antibody injection, generic name: serplulimab injection) is the first innovative monoclonal antibody developed by Henlius. Up to date, 2 indications are approved for marketing in China, 2 NDAs have been accepted by the NMPA, and more than 10 clinical trials are ongoing across the world.
HANSIZHUANG was launched in China in March 2022 and has been approved by the NMPA for the treatment of MSI-H solid tumours and squamous non-small cell lung cancer (sqNSCLC). Its synergy with in-house products of the company and innovative therapies are being actively promoted. It has successively obtained clinical trial licenses in China, the United States, the European Union and other countries and regions to initiate 12 clinical trials on immuno-oncology combination therapies in a wide variety of indications, such as lung cancer, esophageal carcinoma, head and neck squamous cell carcinoma and gastric cancer, etc., and covering the full range of first-line treatments of lung cancers. As of now, the company has enrolled more than 3,100 subjects in China, Turkey, Poland, Georgia and other countries and regions, and the proportion of White is over 30% in two MRCTs, making HANSIZHUANG an anti-PD-1 mAb with one of the largest global clinical data pools. The NDAs of the first-line treatment for squamous non-small cell lung cancer (sqNSCLC), extensive-stage small cell lung cancer (ES-SCLC), and esophageal squamous cell carcinoma (ESCC) have been accepted by the NMPA, which makes HANSIZHUANG potentially the world’s first anti-PD-1 mAb for the first-line treatment of SCLC. Furthermore, HANSIZHUANG was recommended for the treatment of ES-SCLC in the 2022 CSCO Guidelines for Diagnosis and Treatment of Small Cell Lung Cancer (SCLC), and the associated clinical trial became the first study published in JAMA on SCLC immunotherapy. Serplulimab was also granted orphan drug designations by the FDA and EC for the treatment of SCLC, and the first patient has been dosed in a bridging head-to-head trial in the United States to comparing HANSIZHUANG to standard of care Atezolizumab (anti-PD-L1 mAb) for the first-line treatment of ES-SCLC.
About Fosun Pharma
Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196. SH, 02196. HK) is a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China. Fosun Pharma directly operates businesses including pharmaceutical manufacturing, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business.
Fosun Pharma is patient-centered and clinical needs-oriented. The company enriches its innovative product pipeline through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and in-depth incubation. Fosun Pharma has formed technological platforms for innovative small molecule drugs, antibody drugs, and cell therapy with a focus on key disease areas including oncology and immunomodulation, metabolism and digestive system, as well ascentral nervous system. Fosun Pharma also vigorously explores cutting-edge technologies, such as RNA, gene therapy, ADC and PROTAC, to enhance its innovation capabilities.
Guided by the 4IN strategy (Innovation, Internationalization, Intelligentization, and Integration), Fosun Pharma will uphold the development model of “innovation transformation, integrated operation, and steady growth”, with the mission of creating shareholder values through strengthening its independent R&D and external cooperation and enriching its product pipelines, as well as promoting the global networks and enhancing operational efficiency. Fosun Pharma will actively promote the digital and physical business layout in the pharmaceutical and healthcare industry and is committed to becoming a first-class enterprise in the global medical and health market.
For more information, please visit our official website: www.fosunpharma.com.
About Fosun Pharma USA Inc.
Fosun Pharma USA Inc., a subsidiary of Fosun Pharma, was founded in 2017 and continually works to enhance our existing portfolio of specialty pharmaceutical injectables and to build our pipeline with both innovative and generic pharmaceutical drugs. With strategic manufacturing partnerships around the world, Fosun Pharma USA Inc. delivers high-quality products that comply with international standards.
For more information, please visit our official website: https://fosunpharmausa.com/
About Henlius
Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases. Up to date, 5 products have been launched in China, 1 approved for marketing in overseas markets, 15 indications approved worldwide, and 4 New Drug Applications (NDAs) accepted for review in China. Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing and commercialisation. It has established global innovation centers and Shanghai-based manufacturing facilities in line with global Good Manufacturing Practice (GMP), including Xuhui Plant certificated by China and the EU GMP and Songjiang First Plant certificated by China GMP.
Henlius has pro-actively built a diversified and high-quality product pipeline covering over 20 innovative monoclonal antibodies (mAbs) and has continued to explore immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as backbone. Apart from the launched products HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab, trade name in Europe: Zercepac®; trade names in Australia: Tuzucip® and Trastucip®, the first China-developed mAb biosimilar approved both in China and Europe, HANDAYUAN (adalimumab) and HANBEITAI (bevacizumab), the innovative product HANSIZHUANG has been approved by the NMPA for the treatment of MSI-H solid tumours and squamous non-small cell lung cancer (sqNSCLC). Its NDAs for the treatment of extensive-stage small cell lung cancer (ES-SCLC) and esophageal squamous cell carcinoma (ESCC) are under review. What’s more, Henlius has conducted over 20 clinical studies for 15 products and 12 immuno-oncology combination therapies, expanding its presence in major markets as well as emerging markets.
SOURCE Fosun Pharma
Fosun Pharma and MAIA Pharmaceuticals Jointly Announce the Successful Commercialization of Only FDA Approved 20ml Sodium Phenylacetate and Sodium Benzoate (SPSB) Liquid Product
PRINCETON, N.J., Sept. 26, 2022 /PRNewswire/ — Shanghai Fosun Pharma (Group) Co., Ltd. (“Fosun Pharma”, stock code: 600196.SH; 02196.HK) today announced that the 20 ml, Sodium Phenylacetate and Sodium Benzoate (SPSB) liquid product, which is under an exclusive partnership between Fosun Pharma USA Inc. (“Fosun Pharma USA“), the US-based subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196. SH, 02196. HK) and MAIA Pharmaceuticals, Inc. (MAIA), a Princeton, NJ based specialty pharmaceutical company, has been recently launched. Fosun Pharma USA has the exclusive commercial rights of this product in the U.S. market.
Based upon market feedback, the usage of 50ml SPSB, as prescribed, predominantly in the pediatric setting, is subject to extensive product wastage which is a huge cost to the healthcare system. SBSP is available in 20 ml and 50 ml vial sizes. Currently, only MAIA has the FDA approval for the 20 ml vial size.
Rong Yang, Chief Executive Officer of Fosun Pharma USA Inc. and Senior Vice President of Fosun Pharma said, “We are excited that this product in partnership with MAIA has been recently launched which marks a milestone for Fosun Pharma’s business development in the US market.”
Jeremy L. Tatum, Chief Commercial Officer and General Manager of Generics, Fosun Pharma USA Inc. said, “By producing the only commercially available and FDA approved 20 ml SPSB product, MAIA and Fosun Pharma USA are addressing the need to reduce wastage and reduce unnecessary spending on critically needed products. We are ready to ship the Product. For Fosun Pharma USA, this is the first of many 505(b)(2) that will be launched over the next few years.”
About Fosun Pharma USA Inc.
Fosun Pharma USA Inc., a subsidiary of Fosun Pharma, was founded in 2017 and continually works to enhance our existing portfolio of specialty pharmaceutical injectables and to build our pipeline with both innovative and generic pharmaceutical drugs. With strategic manufacturing partnerships around the world, Fosun Pharma USA Inc. delivers high-quality products that comply with international standards.
For more information, please visit our official website: https://fosunpharmausa.com/
About Fosun Pharma
Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196. SH, 02196. HK) is a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China. Fosun Pharma directly operates businesses including pharmaceutical manufacturing, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business.
Fosun Pharma is patient-centered and clinical needs-oriented. The company enriches its innovative product pipeline through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and in-depth incubation. Fosun Pharma has formed technological platforms for innovative small molecule drugs, antibody drugs, and cell therapy with a focus on key disease areas including oncology and immunomodulation, metabolism and digestive system, as well as central nervous system. Fosun Pharma also vigorously explores cutting-edge technologies, such as RNA, gene therapy, ADC and PROTAC, to enhance its innovation capabilities.
Guided by the 4IN strategy (Innovation, Internationalization, Intelligentization, and Integration), Fosun Pharma will uphold the development model of “innovation transformation, integrated operation, and steady growth”, with the mission of creating shareholder values through strengthening its independent R&D and external cooperation and enriching its product pipelines, as well as promoting the global networks and enhancing operational efficiency. Fosun Pharma will actively promote the digital and physical business layout in the pharmaceutical and healthcare industry and is committed to becoming a first-class enterprise in the global medical and health market.
For more information, please visit our official website: www.fosunpharma.com
About MAIA Pharmaceuticals, Inc.
MAIA Pharmaceuticals is a specialty pharmaceutical company that identifies, develops, manufactures and markets innovative and niche hospital products. It specializes in Injectables, Niche Generic, Diagnostics, Hormones, Oncology, Steroids, and Controlled/Sustained Release. MAIA Pharmaceuticals is headquartered in Princeton, NJ.
SOURCE Fosun Pharma
(SHANGHAI, China, June 27, 2022) – Fosun Pharma and Amgen today jointly announced a collaboration and license agreement for Fosun Pharma for the commercialization of Amgen’s Otezla® and Parsabiv® in the Chinese Mainland. The collaboration will enable Amgen to bring the two innovative medicines to Chinese patients with psoriasis and chronic kidney disease more quickly by leveraging Fosun Pharma’s commercial capabilities within China.
Wu Yifang, Chairman of Fosun Pharma said: “We are very pleased to enter into this partnership with Amgen to bring two innovative medicines, Otezla® and Parsabiv®, to Chinese patients. With Fosun Pharma’s experience in the areas of autoimmune diseases, including psoriasis, and chronic kidney diseases over the years, we are well aware of Chinese patients’ urgent needs for better treatment options. Going forward, we will work together with Amgen to leverage our presence in these areas to make the medicines accessible to patients, enabling them to benefit from these innovative medicines as soon as possible, control diseases and improve quality of life.”
“This decision – to enter into a collaboration with a local partner – is consistent with our determined focus to bring our innovative medicines to more Chinese patients more quickly,” said Irene Hsu, Vice President & General Manager of Amgen China, ” By out-licensing these two products to a partner with the presence, expertise and credibility of Fosun Pharma in these therapeutic areas, we can give full play to both companies’ advantages to ensure more patients are able to benefit from these innovative medicines, while enabling Amgen to focus on our core general medicines business in cardiovascular disease and bone health in China.”
Otezla® (apremilast tablets) was approved by the National Medical Products Administration of China (NMPA) in August 2021 for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. This approval makes Otezla® the first and currently the only oral phosphodiesterase 4 (PDE4) inhibitor for the treatment of plaque psoriasis in China, providing an additional choice for Chinese patients to manage disease and improve quality of life. China has about 6.5 million patients with psoriasis[1], and 57.3% of them are moderate-to-severe cases[2].
Parsabiv® has been approved by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) in November 2016 and February 2017 respectively for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. Currently Parsabiv® is in the process of market authorization approval (MAA) in China. SHPT is one of the common complications of CKD patients on hemodialysis. The prevalence of adult CKD in China is 10.8%[3]. Data show that by the end of 2019, the number of dialysis patients in China has increased to 735,000[4], among which hemodialysis is the main therapy for dialysis patients in China. The incidence of SHPT in hemodialysis patients is 47%-58%[4].
About Fosun Pharma
Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196. SH, 02196. HK) is a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China. Fosun Pharma directly operates businesses including pharmaceutical manufacturing, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business.
Fosun Pharma is patient-centered and clinical needs-oriented. The company enriches its innovative product pipeline through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and in-depth incubation. Fosun Pharma has formed technological platforms for innovative small molecule drugs, antibody drugs, and cell therapy with a focus on key disease areas including oncology and immunomodulation, metabolism and digestive system, and central nervous system. Fosun Pharma also vigorously explores cutting-edge technologies, such as RNA, oncolytic viruses, gene therapy and PROTAC, to enhance its innovation capabilities.
Guided by the 4IN strategy (Innovation, Internationalization, Integration, and Intelligentization), Fosun Pharma will uphold the development model of “innovation transformation, integrated operation, and steady growth”, with the mission of creating shareholder values as well as promoting the global networks through strengthening its innovative R&D and in-licensing ability and enriching its product pipelines. Fosun Pharma will actively promote the digital and physical business layout in the pharmaceutical and healthcare industry and is committed to becoming a first-class enterprise in the global mainstream medical and health market.
For more information, please visit our official website: www.fosunpharma.com.
Fosun Pharma Forward-looking statements:
This press release contains forward-looking statements. All statements other than statements of historical fact contained in this press release, including, without limitation, the discussions of Fosun Pharma’s business strategies and expectations concerning future operations, margins, profitability, liquidity and capital resources, the future development of Fosun Pharma’s industry and the future development of the general economy of Fosun Pharma’s key markets and any statements preceded by, followed by or that include words and expressions such as “expect”, “seek”, “believe”, “plan”, “intend”, “estimate”, “project”, “anticipate”, “may”, “will”, “would” and “could” or similar words or statements, as they relate to Fosun Pharma’s or its management, are intended to identify forward-looking statements. These statements are subject to certain known and unknown risks, uncertainties and assumptions, which may cause Fosun Pharma’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Accordingly, you should not place undue reliance on any forward-looking information. Subject to the requirements of applicable laws, rules and regulations, Fosun Pharma does not have any and undertakes no obligation to update or otherwise revise the forward- looking statements in this press release, whether as a result of new information, future events or developments or otherwise. In this press release, statements of or references to Fosun Pharma’s intentions are made as of the date of this press release. Any such intentions may change in light of future developments. All forward-looking statements contained in this press release are qualified by reference to the cautionary statements set out above.
About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing, and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
For more information, visit http://www.amgen.com and follow us on http://www.twitter.com/amgen.
About Amgen China
Amgen entered China in 2012 on a mission to serve patients by using science and biotechnology to improve health for Chinese patients and societies. With its headquarters in Shanghai, Amgen China is present in more than 100 cities across the country. In China, Amgen strives to bring innovative therapies to patients in a bid to address the huge unmet needs in in our priority therapeutic areas including cardiovascular disease, bone health, inflammation, and hematology/oncology.
For more information, visit www.amgen.cn and follow us on Amgen China Corporate WeChat account “安进Amgen”.
Reference:
1. 中华医学会皮肤性病学分会银屑病专业委员会.中国银屑病诊疗指南(2018简版)[J].中华皮肤科杂志,2019,52(4):223-230.
2. Chen, K., Wang, G., Jin, H., Xu, J., Zhu, X., Zheng, M., & Gu, H. (2017). Clinic characteristics of psoriasis in China: a nationwide survey in over 12000 patients. Oncotarget, 8(28), 46381–46389.
3. Zhang, L., Wang, F., Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012, 379(9818): 815-822.
4. 全国血液净化病例信息登记系统, 2020.
